INDSWFTLABInd-Swift Laboratories Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticancer, hypercholesterolemia, antimuscarinic, antimigraine, and thrombocytopenia. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, azithromycin dihydrate, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, clopidogrel hydrochloride, dapoxetine hydrochloride, donepezil hydrochloride, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nateglinide, nitazoxanide, nitrosamine, pazopanib hydrochloride, quetiapine hemifumarate, raltegravir potassium, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services. The company exports its products. Ind-Swift Laboratories Limited was incorporated in 1995 and is based in Manimajra, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on INDSWFTLAB — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Debt/Equity: 0.01
- • Promoter holding: 59.3%
- • RSI: 69
- • Price vs EMA21: above
- • Price vs SMA50: above
- • 1-month return: +29.9%
Bull case
- • Debt/Equity: 0.01
- • Promoter holding: 59.3%
- • RSI: 69
- • Price vs EMA21: above
Bear case
- • Revenue growth: -66.6% YoY
- • Profit growth: -94.8% YoY
- • MACD: bearish
- • Volume: 0.4x 20-day average
Key risks
- • Weak fundamentals — technical strength may not sustain
- • Revenue growth: -66.6% YoY
- • Profit growth: -94.8% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹19.52). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.